Status:
RECRUITING
Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds
Lead Sponsor:
NuScience Medical Biologics, LLC
Collaborating Sponsors:
SygNola, LLC
Conditions:
Open Wound
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a randomized controlled crossover trial evaluating the efficacy of NeoThelium FT in conjunction with standard of care vs. standard of care alone in treating chronic open wounds.
Detailed Description
This research will take place across multiple medical centers, where both researchers and participants will know which treatment is being used (open label). Patients who agree to participate and meet ...
Eligibility Criteria
Inclusion
- Male or Female, 18 years of age or older
- Subject has a medical diagnosis of "other" Open wound
- Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC
- Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening
- Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization
- Subject has an Open wound without infection or clinically visible exposed bone
- Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit
- Index ulcer has a maximum depth of 1cm at screening visit 1
- The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization
- Adequate circulation of wounds located below the knee demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization.
- Index ulcer is free of infection prior to randomization and during screening phase.
- Index ulcer is free of necrotic debris prior to NeoThelium FT application
- Female subjects of childbearing potential having a negative pregnancy test prior to randomization
- Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization.
- Subject is able and willing to follow the protocol requirements
- Subject had signed informed consent
- If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm
Exclusion
- Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound"
- Subject has a known life expectancy of \<1 year
- Subject is unable to comply with protocol treatment
- Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing.
- Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound
- Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator
- Known contraindications to tissue-engineered allograft
- Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing
- Subject is pregnant or breastfeeding
- Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study
- Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization
- Open wound with active infection
- Wound depth with visible exposed bone
- HBOT within 14 days prior to randomization
- Revascularization surgery on the index wound leg within 30 days of screening phase
- Index wound suspicious of neoplasm in the opinion of the principal investigator
Key Trial Info
Start Date :
October 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT06918561
Start Date
October 16 2025
End Date
October 1 2026
Last Update
December 4 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
MedCentris of Hammond
Hammond, Louisiana, United States, 70403
2
MedCentris of Slidell
Slidell, Louisiana, United States, 70458
3
MedCentris of D'iberville
D'Iberville, Mississippi, United States, 39540